ClinicalTrials.gg
CompletedNCT02093026Updated Mar 13, 2017Results posted

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

A Phase 2 interventional study of Rituximab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 92 sites in 16 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
465
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
7th of 63
465 · median 159
Started
2002
the only one that year
Phase 2
11 of 63
1 open now
Registered
47th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is the only one that started in 2002, is one of 11 in phase 2, and was the 47th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of participants who were previously randomized into studies WA16291 (NCT02693210) or WA17043/U2644g (NCT00074438). The study permits multiple re-treatments until the protocol-defined end-of-treatment date (31 December 2011). Participants will then enter a safety follow-up (SFU) period of at least 48 weeks. This will provide at least 7 years follow-up data on all participants initially randomized into WA16291 or WA17043/U2644g. Approximately 600 participants will potentially be eligible to enter this open label extension study from their respective feeder studies.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participants with active RA
  • completed 24 weeks of treatment in WA16291 or WA17043
  • eligible for re-treatment, based on clinical symptoms (Disease Activity Score in 28 joints >=2.6)
  • females of using reliable

Exclusion criteria

Exclusion Criteria:

  • participants who participated in rituximab studies WA16291 or WA17043 but withdrew into the safety follow-up phases of these trials
  • previous rituximab non-responders
  • current treatment with any other disease-modifying drug (apart from methotrexate), or any anti-tumor necrosis factor alfa, anti-interleukin-1, or other biologic therapies
  • participants with known active infection of any kind
  • evidence of any new or uncontrolled concomitant disease or development of any new which would preclude repeat treatment with rituximab
  • history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • female participants who are pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
465 participants (actual)

Study arms

  • Experimental
    Rituximab

    Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (\>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first \[Day 1\] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints \>=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.

    Drug: Rituximab · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Folic Acid

Interventions

  • Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.

    Also known as: MabThera, Rituxan

  • Participants will receive methotrexate 10-25 mg/week orally or parenterally.

  • Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.

  • Participants will receive folic acid \>= 5 mg/week or equivalent.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course

    A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in tender joint count (TJC) and swollen joint count (SJC) (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after first course of rituximab (up to approximately 26 weeks)

  2. Percentage of Participants With ACR20 Response After Second Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after second course of rituximab (median duration of 90.9 weeks)

  3. Percentage of Participants With ACR20 Response After Third Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after third course of rituximab (median duration of 162.9 weeks)

  4. Percentage of Participants With ACR20 Response After Fourth Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after fourth course of rituximab (median duration of 232 weeks)

  5. Percentage of Participants With ACR20 Response After Fifth Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after fifth course of rituximab (median duration of 297.3 weeks)

  6. Percentage of Participants With ACR20 Response After Sixth Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after sixth course of rituximab (median duration of 354.4 weeks)

  7. Percentage of Participants With ACR20 Response After Seventh Course

    A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after seventh course of rituximab (median duration of 406.7 weeks)

Secondary outcomes

  1. Percentage of Participants With ACR50 and ACR70 Response

    A participant had an ACR50 and ACR70 response if there was at least a 50% or 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of disease activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (CRP or ESR). The ACR50 and ACR70 responses were compared to Baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  2. American College of Rheumatology Index of Improvement (ACRn) Response

    The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (patient's assessment of disease activity; patient's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value \[either CRP or ESR\]). The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA. ACRn scores were calculated considering the original baseline in the precursor studies WA16291 or WA17043.

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  3. Percentage of Participants With Low Disease Activity and Clinical Remission Based on DAS28-ESR

    DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hour\]), and Patient's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*square root (sqrt)(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*Patient's Global Assessment of Disease Activity. Total score range: 0-10, higher score=more disease activity. DAS28-ESR \<= 3.2 implied low disease activity (LDA) and DAS28-ESR \<2.6 = clinical remission.

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  4. Percentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate'

    DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and Physician's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\*Patient's Global Assessment of Disease Activity. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline greater than (\>) 1.2 with a DAS28 score less than or equal to (≤) 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 to less than or equal to (≤) 5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1.

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  5. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  6. Change From Baseline in Total Rheumatoid Factors (RF) at 24 Weeks Following Each Course

    Time frame: 24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

  7. Percentage of Participants Who Discontinued Treatment Due to Insufficient Response

    Time frame: First, second, third, fourth, fifth, sixth, and seventh course of rituximab (up to a median of approximately 2, 62, 124, 186, 248, 310, and 372 weeks, respectively)

  8. Time Since Last Treatment Course

    Time since last treatment course = The last day of the last dose of rituximab to date of last contact. Date of last contact is the last available date of efficacy, complete medication start date, laboratory, adverse event assessments, early withdrawal visit, date of last contact, or date of death.

    Time frame: Baseline up to 10 years

07

Results

Posted Mar 13, 2017
Limitations and caveats
The interpretation of the efficacy data over time should take into consideration that only the response of participants who continued in the study and received further courses of rituximab was captured.

Participant flow

This study included participants who had previously participated in studies WA16291 (NCT02693210) or WA17043 (NCT00074438).

Participant flow — Overall Study
MilestoneRituximab
Started465
Completed272
Not completed193
Withdrew: Adverse event26
Withdrew: Death10
Withdrew: Other157

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course

A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in tender joint count (TJC) and swollen joint count (SJC) (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after first course of rituximab (up to approximately 26 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course
percentage of participantsRituximab
Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course67.1
PrimaryPercentage of Participants With ACR20 Response After Second Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after second course of rituximab (median duration of 90.9 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Second Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Second Course70.8
PrimaryPercentage of Participants With ACR20 Response After Third Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after third course of rituximab (median duration of 162.9 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Third Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Third Course73.2
PrimaryPercentage of Participants With ACR20 Response After Fourth Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after fourth course of rituximab (median duration of 232 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Fourth Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Fourth Course75.1
PrimaryPercentage of Participants With ACR20 Response After Fifth Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after fifth course of rituximab (median duration of 297.3 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Fifth Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Fifth Course69.7
PrimaryPercentage of Participants With ACR20 Response After Sixth Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after sixth course of rituximab (median duration of 354.4 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Sixth Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Sixth Course68.2
PrimaryPercentage of Participants With ACR20 Response After Seventh Course

A participant had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR). The ACR20 response was compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after seventh course of rituximab (median duration of 406.7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response After Seventh Course
percentage of participantsRituximab
Percentage of Participants With ACR20 Response After Seventh Course59.5
SecondaryPercentage of Participants With ACR50 and ACR70 Response

A participant had an ACR50 and ACR70 response if there was at least a 50% or 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of disease activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0=no disease activity to 100=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0=no pain to 100=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (CRP or ESR). The ACR50 and ACR70 responses were compared to Baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants With ACR50 and ACR70 Response
percentage of participantsRituximab
ACR50: 24 weeks after first course39.4
ACR50: 24 weeks after second course41.9
ACR50: 24 weeks after third course44.8
ACR50: 24 weeks after fourth course46.9
ACR50: 24 weeks after fifth course40.0
ACR50: 24 weeks after sixth course40.0
ACR50: 24 weeks after seventh course36.5
ACR70: 24 weeks after first course16.3
ACR70: 24 weeks after second course21.6
ACR70: 24 weeks after third course20.0
ACR70: 24 weeks after fourth course20.0
ACR70: 24 weeks after fifth course18.9
ACR70: 24 weeks after sixth course20.9
ACR70: 24 weeks after seventh course18.9
SecondaryAmerican College of Rheumatology Index of Improvement (ACRn) Response

The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (patient's assessment of disease activity; patient's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value \[either CRP or ESR\]). The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA. ACRn scores were calculated considering the original baseline in the precursor studies WA16291 or WA17043.

Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Reported as:
Mean · units on a scale
American College of Rheumatology Index of Improvement (ACRn) Response
units on a scaleRituximab
24 weeks after first course31.07 ± 50.188
24 weeks after second course34.15 ± 58.769
24 weeks after third course36.93 ± 44.912
24 weeks after fourth course39.59 ± 39.393
24 weeks after fifth course33.76 ± 48.309
24 weeks after sixth course29.74 ± 57.197
24 weeks after seventh course24.87 ± 51.336
SecondaryPercentage of Participants With Low Disease Activity and Clinical Remission Based on DAS28-ESR

DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hour\]), and Patient's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*square root (sqrt)(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*Patient's Global Assessment of Disease Activity. Total score range: 0-10, higher score=more disease activity. DAS28-ESR \<= 3.2 implied low disease activity (LDA) and DAS28-ESR \<2.6 = clinical remission.

Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity and Clinical Remission Based on DAS28-ESR
percentage of participantsRituximab
LDA: 24 weeks after first course24.3
LDA: 24 weeks after second course30.1
LDA: 24 weeks after third course29.3
LDA: 24 weeks after fourth course28.0
LDA: 24 weeks after fifth course23.8
LDA: 24 weeks after sixth course27.3
LDA: 24 weeks after seventh course24.7
Remission: 24 weeks after first course11.3
Remission: 24 weeks after second course16.8
Remission: 24 weeks after third course17.1
Remission: 24 weeks after fourth course15.7
Remission: 24 weeks after fifth course15.7
Remission: 24 weeks after sixth course17.3
Remission: 24 weeks after seventh course13.7
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate'

DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and Physician's Global Assessment of Disease Activity (VAS: 0=no disease activity to 100=maximum disease activity). DAS28-ESR = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\*Patient's Global Assessment of Disease Activity. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline greater than (\>) 1.2 with a DAS28 score less than or equal to (≤) 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 to less than or equal to (≤) 5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1.

Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate'
percentage of participantsRituximab
Moderate: 24 weeks after first course57.8
Moderate: 24 weeks after second course58.5
Moderate: 24 weeks after third course59.5
Moderate: 24 weeks after fourth course60.9
Moderate: 24 weeks after fifth course62.1
Moderate: 24 weeks after sixth course57.0
Moderate: 24 weeks after seventh course60.0
Good: 24 weeks after first course24.3
Good: 24 weeks after second course30.4
Good: 24 weeks after third course29.1
Good: 24 weeks after fourth course27.9
Good: 24 weeks after fifth course24.3
Good: 24 weeks after sixth course27.1
Good: 24 weeks after seventh course25.7
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course

The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at 24 Weeks Following Each Course
units on a scaleRituximab
24 weeks after first course-0.51 ± 0.555
24 weeks after second course-0.48 ± 0.556
24 weeks after third course-0.43 ± 0.532
24 weeks after fourth course-0.47 ± 0.529
24 weeks after fifth course-0.44 ± 0.541
24 weeks after sixth course-0.38 ± 0.600
24 weeks after seventh course-0.37 ± 0.576
SecondaryChange From Baseline in Total Rheumatoid Factors (RF) at 24 Weeks Following Each Course
Time frame:
24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Discontinued Treatment Due to Insufficient Response
Time frame:
First, second, third, fourth, fifth, sixth, and seventh course of rituximab (up to a median of approximately 2, 62, 124, 186, 248, 310, and 372 weeks, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Treatment Due to Insufficient Response
percentage of participantsRituximab
First course1.1
Second course2.3
Third course2.0
Fourth course2.0
Fifth course0.8
Sixth course0.0
Seventh course0.6
SecondaryTime Since Last Treatment Course

Time since last treatment course = The last day of the last dose of rituximab to date of last contact. Date of last contact is the last available date of efficacy, complete medication start date, laboratory, adverse event assessments, early withdrawal visit, date of last contact, or date of death.

Time frame:
Baseline up to 10 years
Reported as:
Mean · years
Time Since Last Treatment Course
yearsRituximab
Time Since Last Treatment Course4.21 ± 2.234

Adverse events

Collected over Baseline up to approximately 11 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—230/465 (49.5%)422/465 (90.8%)
Placebo—12/127 (9.4%)93/127 (73.2%)
Most frequent serious events
Showing 10 of 256
Most frequent serious events
EventRituximabPlacebo
Rheumatoid arthritisMusculoskeletal and connective tissue disorders19/4651/127
FallInjury, poisoning and procedural complications19/4650/127
PneumoniaInfections and infestations13/4651/127
OsteoarthritisMusculoskeletal and connective tissue disorders12/4650/127
Myocardial infarctionCardiac disorders9/4650/127
Urinary tract infectionInfections and infestations7/4650/127
Lower respiratory tract infectionInfections and infestations6/4650/127
Joint destructionMusculoskeletal and connective tissue disorders6/4650/127
Device dislocationGeneral disorders6/4650/127
CellulitisInfections and infestations5/4650/127
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRituximabPlacebo
Rheumatoid arthritisMusculoskeletal and connective tissue disorders236/46554/127
Infusion related reactionGeneral disorders203/46525/127
Upper respiratory tract infectionInfections and infestations153/4657/127
NasopharyngitisInfections and infestations145/46513/127
BronchitisInfections and infestations108/4656/127
Urinary tract infectionInfections and infestations102/4659/127
HypertensionVascular disorders93/4656/127
DiarrhoeaGastrointestinal disorders85/4659/127
Back painMusculoskeletal and connective tissue disorders84/4657/127
HeadacheNervous system disorders82/4659/127

Baseline characteristics

Safety Population included all participants who received any part of an infusion of study medication under Study WA16855.

Age, Continuous
Age, Continuous(years)Rituximab
Mean51 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female364
Male101
08

Study locations

92 sites
  • Birmingham, Alabama 35294, United States
  • Peoria, Arizona 85381, United States
  • Little Rock, Arkansas 72205, United States
  • La Jolla, California 92037, United States
  • Long Beach, California 92813, United States
  • Rancho Mirage, California 92270, United States
  • San Diego, California 92108, United States
  • Colorado Springs, Colorado 80920, United States
  • Aventura, Florida 33180, United States
  • Boca Raton, Florida 33486, United States
  • Fort Lauderdale, Florida 33334, United States
  • Largo, Florida 33773, United States
  • South Miami, Florida 33143, United States
  • Boise, Idaho 83702, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202-5149, United States
  • Indianapolis, Indiana 46260, United States
  • Boston, Massachusetts 02215, United States
  • Minneapolis, Minnesota 55416, United States
  • Saint Louis, Missouri 63141, United States
  • Lebanon, New Hampshire 03756, United States
  • Voorhees, New Jersey 08043, United States
  • Great Neck, New York 11021, United States
  • Plainview, New York 11803, United States
  • Rochester, New York 14618, United States
  • Smithtown, New York 11787, United States
  • Greenville, North Carolina 27834, United States
  • Winston Salem, North Carolina 27157, United States
  • Beachwood, Ohio 44122, United States
  • Dayton, Ohio 45402, United States
  • Mayfield, Ohio 44143, United States
  • Tulsa, Oklahoma 74104, United States
  • Tulsa, Oklahoma 74135, United States
  • Portland, Oregon 97239, United States
  • Duncansville, Pennsylvania 16635, United States
  • Dallas, Texas 75231, United States
  • Houston, Texas 77074, United States
  • Salt Lake City, Utah 84132, United States
  • Seattle, Washington 98104, United States
  • Glendale, Wisconsin 53217, United States
  • Wausau, Wisconsin 54401, United States
  • Maroochydore, Queensland 4558, Australia
  • Melbourne, Victoria 3168, Australia
  • Perth, Western Australia 6979, Australia
  • Gent, 9000, Belgium
  • Curtiba, PR 80030-110, Brazil
  • Campinas, SP 13083-888, Brazil
  • Sao Paulo, SP 04026-000, Brazil
  • Calgary, Alberta T2N 4Z6, Canada
  • Vancouver, British Columbia V5Z 1L7, Canada
  • St John's, Newfoundland and Labrador A1A 5E8, Canada
  • London, Ontario N6A 4V2, Canada
  • Praha, 128 50, Czech Republic
  • Heinola, 18120, Finland
  • Helsinki, 00290, Finland
  • Köln, 50924, Germany
  • Leipzig, 04103, Germany
  • Ratingen, 40882, Germany
  • Regensburg, 93053, Germany
  • Wuerzburg, 97080, Germany
  • Haifa, 3109601, Israel
  • Haifa, 3339419, Israel
  • Modena, Emilia-Romagna 41100, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Genova, Liguria 16132, Italy
  • Milano, Lombardia 20157, Italy
  • Mexico City, 06726, Mexico
  • Mexico City, 10700, Mexico
  • Mexico, 44620, Mexico
  • Monterrey, 64460, Mexico
  • Auckland City, 0620, New Zealand
  • Auckland, 2025, New Zealand
  • Bialystok, 15-351, Poland
  • Lublin, 20-022, Poland
  • Poznan, 61-545, Poland
  • Warszawa, 02-637, Poland
  • Wroclaw, 50-556, Poland
  • Merida, Badajoz 06800, Spain
  • Santiago de Compostela, La Coruña 15706, Spain
  • La Laguna, Tenerife 38320, Spain
  • Madrid, 28006, Spain
  • Madrid, 28007, Spain
  • Madrid, 28046, Spain
  • Sevilla, 41014, Spain
  • Göteborg, 413 45, Sweden
  • Stockholm, 171 76, Sweden
  • Birmingham, B29 6JD, United Kingdom
  • Cambridge, CB2 2QQ, United Kingdom
  • Cannock, WS11 5XY, United Kingdom
  • Leeds, LS7 4SA, United Kingdom
  • Stoke-on-trent, ST6 7AG, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
Mar 20, 2014
Start
Aug 2002
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Mar 13, 2017
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02093026
Lead sponsor
Hoffmann-La Roche
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
Aug 2002
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Mar 13, 2017
Last update
Mar 13, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion